Travere Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Hi, everyone. Welcome. It's great to see everyone in person. This is the fourth day of the JPMorgan Healthcare Conference. My name is Luka Kachukhashvili. I'm an associate here in the Healthcare Investment Banking team.
It's my absolute pleasure to introduce Travere Therapeutics. Joining us today will be Eric Dube, the CEO of Travere. With that, I hand it over to you.
Luka, thank you, and JPMorgan for hosting us. I couldn't be more excited and grateful to be able to share the opportunity to talk about Travere. It is perhaps the most important year for us in our 8-year history, but also for the space within rare kidney disease that really were at the forefront of what I believe is a renaissance in being able to bring hope and new therapies for patients living with rare kidney disease.
In my presentation, I will be sharing some forward-looking statements. So I'd encourage you to go to look at our SEC filings for additional language there. But I want to start
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |